Streetbeat News

Analyst Ratings

NGMS

Truist Securities analyst Barry Jonas has reiterated a Hold rating on NeoGames (NASDAQ:NGMS) and maintained a price target of $29.5.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 3:11 pm

ZION

Truist Securities analyst Brandon King has reaffirmed a Buy rating on Zions Bancorp (NASDAQ:ZION) and increased the price target from $34 to $40.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 3:06 pm

MNST

Piper Sandler analyst Michael Lavery has maintained a Neutral rating on Monster Beverage (NASDAQ:MNST) and increased the price target from $50 to $58.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 3:05 pm

FND

Truist Securities analyst Keith Hughes has reaffirmed a Buy rating on Floor & Decor Holdings (NYSE:FND) and increased the price target from $97 to $102.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 3:03 pm

MRO

Stifel analyst Derrick Whitfield has maintained a Buy rating on Marathon Oil (NYSE:MRO) but has reduced the price target from $40 to $39.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 3:02 pm

RRC

Over the past 3 months, 13 Wall Street analysts have provided ratings for Range Resources (NYSE:RRC), with an average price target of $37.92, representing an upside from the current price of $33.73. The consensus includes 5 bullish, 5 somewhat bullish, 2 indifferent, and 1 somewhat bearish ratings. The average price target has increased by 8.59% from the previous target of $34.92.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 3:01 pm

TYL

Over the past 3 months, 6 Wall Street analysts have published their opinions on Tyler Technologies (NYSE:TYL), with 3 giving a bullish and 3 a somewhat bullish rating. The average 12-month price target for TYL is $478.33, with a high of $510.00 and a low of $450.00. This target has increased by 3.24% over the past month. Analyst ratings are based on company data, financial statements, and insider information, and are intended to predict stock performance.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 3:00 pm

PTCT

PTC Therapeutics (NASDAQ:PTCT) has received mixed analyst ratings in the last quarter, with 2 bullish, 1 somewhat bullish, 7 indifferent, 1 somewhat bearish, and 2 bearish ratings. The average 12-month price target among 13 analysts is $30.23, which is a 27.85% decrease from the previous target of $41.90. Ratings suggest a cautious outlook on the stock.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 3:00 pm

MIRM

Over the past 3 months, 11 Wall Street analysts have provided ratings for Mirum Pharmaceuticals (NASDAQ:MIRM), with an average price target of $60.82, which is significantly higher than the current price of $32.32. The consensus among these analysts is positive, with 3 bullish and 8 somewhat bullish ratings. However, the current average price target has decreased by 17.25% from the previous target of $73.50.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 3:00 pm

CRNX

Crinetics Pharmaceuticals (NASDAQ:CRNX) received 8 analyst ratings in the last quarter, with an average price target of $41.25, representing an upside from the current price of $30.01. The ratings include 2 bullish and 6 somewhat bullish, with no indifferent, somewhat bearish, or bearish ratings. The new average price target is a 6.25% decrease from the previous target of $44.00. Analysts use various methods to rate stocks, and their predictions can influence trading decisions.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 3:00 pm